Indoximod

Drug Profile

Indoximod

Alternative Names: 1 MT; 1-methyl-D-tryptophan; 1-methyltryptophan; d-1-methyltryptophan; D-1MT; NLG-001; NLG-8189; NSC-721782

Latest Information Update: 25 Aug 2016

Price : $50

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer National Cancer Institute (USA); NewLink Genetics Corporation; University of Minnesota
  • Class Amino acids; Antineoplastics; Indoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I/II Acute myeloid leukaemia; Glioma; Malignant melanoma; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 13 Jul 2016 NewLink Genetics Corporation plans a phase Ib/IIa trial for Acute myeloid leukaemia (Combination therapy, Newly diagnosed, ) in USA (PO) (NCT02835729)
  • 06 Jul 2016 Adverse event data from a phase I/II trial in Pancreatic cancer (Combination therapy, Metastatic disease) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 01 Jul 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, Newly diagnosed) in USA (PO) (NCT02835729)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top